. 2024 Nov 20;15:1461571. doi: 10.3389/fphar.2024.1461571

TABLE 5.

The base case analysis.

Treatment	Cost	QALY	Incremental cost	Incremental QALY	INHB	INMB	ICER
Tislelizumab plus chemotherapy (China)	28,297.65	1.00	8,034.40	0.21	0.002	58.29	37,768.48
Chemotherapy (China)	20,263.25	0.78	8,034.40	0.21	0.002	58.29	37,768.48
Tislelizumab plus chemotherapy (TAP ≥ 5%) (China)	27,746.58	1.16	8,594.51	0.36	0.13	5,112.34	23,853.52
Chemotherapy (TAP ≥ 5%) (China)	19,152.07	0.80	8,594.51	0.36	0.13	5,112.34	23,853.52
Tislelizumab plus chemotherapy (US)	188,096.92	1.03	114,300.64	0.23	−0.53	−80,200.47	502,786.22
Chemotherapy (US)	73,796.28	0.80	114,300.64	0.23	−0.53	−80,200.47	502,786.22
Tislelizumab plus chemotherapy (TAP ≥ 5%) (US)	193,023.84	1.20	123,696.77	0.38	−0.44	−65,965.63	321,395.28
Chemotherapy (TAP ≥ 5%) (US)	69,327.07	0.82	123,696.77	0.38	−0.44	−65,965.63	321,395.28

QALY: Quality-adjusted life year, ICER: Incremental cost-effectiveness ratio, INMB: the incremental net monetary benefits, INHB: the incremental net health benefits, TAP: PD-L1, tumor area proportion.